Disease Information

General Information of the Disease (ID: DIS00198)

• Name: Unclassified pleomorphic sarcoma
• ICD: ICD-11: 2B54

Type(s) of Resistant Mechanism of This Disease

  UAPP: Unusual Activation of Pro-survival Pathway

Drug Resistance Data Categorized by Drug

Investigative Drug(s) 2 drug(s) in total

GDC-0623

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Unusual Activation of Pro-survival Pathway (UAPP)

Key Molecule: GTPase HRas (HRAS) [1]

• Resistant Disease: Unclassified pleomorphic sarcoma [ICD-11: 2B54.0]
• Molecule Alteration: Missense mutation; p.G12V
• Resistant Drug: GDC-0623
• Experimental Note: Discovered Using In-vivo Testing Model
• Cell Pathway Regulation: RAS signaling pathway; Activation; hsa04014
• In Vitro Model: HEK293T cells; Kidney; Homo sapiens (Human); CVCL_0063
• In Vitro Model: NIH3T3 cells; Embryo; Homo sapiens (Human); N.A.
• In Vivo Model: SCID/Beige mice model; Mus musculus
• Experiment for Molecule Alteration: qRT-PCR; Western blotting assay
• Experiment for Drug Resistance: Cell viability assay
• Mechanism Description: Hras G12V mutation changed the drug target,impairing the ability to inhibit RAS-RAF-MEK-ERK signaling.

SCH772984

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Unusual Activation of Pro-survival Pathway (UAPP)

Key Molecule: GTPase HRas (HRAS) [1]

• Resistant Disease: Unclassified pleomorphic sarcoma [ICD-11: 2B54.0]
• Molecule Alteration: Missense mutation; p.G12V
• Resistant Drug: SCH772984
• Experimental Note: Discovered Using In-vivo Testing Model
• Cell Pathway Regulation: RAS signaling pathway; Activation; hsa04014
• In Vitro Model: HEK293T cells; Kidney; Homo sapiens (Human); CVCL_0063
• In Vitro Model: NIH3T3 cells; Embryo; Homo sapiens (Human); N.A.
• In Vivo Model: SCID/Beige mice model; Mus musculus
• Experiment for Molecule Alteration: qRT-PCR; Western blotting assay
• Experiment for Drug Resistance: Cell viability assay
• Mechanism Description: Hras G12V mutation changed the drug target,impairing the ability to inhibit RAS-RAF-MEK-ERK signaling.

References

• Ref 1: Sensitivity and Resistance of Oncogenic RAS-Driven Tumors to Dual MEK and ERK Inhibition .Cancers (Basel). 2021 Apr 13;13(8):1852. doi: 10.3390/cancers13081852. 10.3390/cancers13081852